Observed Outcomes Associated With Fluticasone Propionate/Salmeterol Xinafoate or Inhaled Corticosteroids in Asthma Patients
Status:
Completed
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
This is an observational retrospective analysis of linked pharmacy and medical claims data
from IMS Health/Pharmetrics database. which is a comprehensive, de-identified United States
(US) healthcare claims database that is representative of the non-elderly, insurance-carrying
population, The total population is 35.4 million. The average length of follow-up is 2.7
years mean (2.2 years median).
Subjects will be identified in the database that have at least one ICD-9 diagnostic code
(493.xx) for asthma and at least 1 asthma treatment within a 12-month period prior to the
index use of fluticsasone propionate/salmeterol xinafoate or inhaled corticosteroids.
Subjects will be followed in the database until they have the event of interest
(asthma-related emergency department visit, hospitalization, or oral corticosteroid use or
combination of asthma-related emergency department/hospitalization or asthma-related
emergency department/hospitalization/oral corticosteroids) or until they are lost to follow
up whichever comes first. Subjects can be censored if they leave the database, have the event
of interest, or are dispensed another asthma controller other than the medication of
interest. All outcomes will be assessed in the follow-up period. Time-dependent statistical
models adjusting for differences in baseline (pre-index) asthma and patient demographics will
be used to compare asthma events.
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Fluticasone Fluticasone Propionate, Salmeterol Xinafoate Drug Combination Salmeterol Xinafoate Xhance